Analysts Set The Cooper Companies, Inc. (NASDAQ:COO) Target Price at $110.25

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have received an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $110.25.

A number of research firms recently weighed in on COO. Wells Fargo & Company raised their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. Citigroup decreased their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reduced their price objective on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th.

Cooper Companies Stock Up 1.3 %

Shares of COO stock opened at $84.98 on Tuesday. The company’s fifty day simple moving average is $89.52 and its two-hundred day simple moving average is $97.53. Cooper Companies has a 52 week low of $77.05 and a 52 week high of $112.38. The stock has a market cap of $16.99 billion, a P/E ratio of 43.58, a PEG ratio of 2.25 and a beta of 1.02. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of COO. Wellington Management Group LLP boosted its stake in shares of Cooper Companies by 517.1% during the fourth quarter. Wellington Management Group LLP now owns 175,152 shares of the medical device company’s stock valued at $16,102,000 after purchasing an additional 146,771 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Cooper Companies by 3.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 9,370 shares of the medical device company’s stock valued at $861,000 after buying an additional 309 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Cooper Companies during the 4th quarter valued at about $17,392,000. Jefferies Financial Group Inc. boosted its position in Cooper Companies by 138.9% in the 4th quarter. Jefferies Financial Group Inc. now owns 48,514 shares of the medical device company’s stock valued at $4,460,000 after buying an additional 28,204 shares during the period. Finally, Mackenzie Financial Corp grew its stake in Cooper Companies by 12.4% in the 4th quarter. Mackenzie Financial Corp now owns 19,910 shares of the medical device company’s stock worth $1,830,000 after acquiring an additional 2,193 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.